par Kerpel-Fronius, Sandor;Becker, Sander;Barrett, Jane;Brun, Johan;Carlesi, Roberto;Chan, Anthony A.W.;Collia, Luis L.F.;Dubois, David ;Kleist, Peter;Koski, Greg;Kurihara, Chieko;Laranjeira, Luis L.F.;Schenk, Johanna;Silva, Honorio
Référence Frontiers in Pharmacology, 9, SEP, 843
Publication Publié, 2018-09
Référence Frontiers in Pharmacology, 9, SEP, 843
Publication Publié, 2018-09
Article révisé par les pairs
Résumé : | The complexity of developing and applying increasingly sophisticated new medicinal products has led to the participation of many non-medically qualified scientists in multi-disciplinary non-clinical and clinical drug development teams world-wide. In this introductory paper to the "IFAPP International Ethics Framework for Pharmaceutical Physicians and Medicines Development Scientists" it is argued that all members of such multidisciplinary teams must share the scientific and ethical responsibilities since they all influence directly or indirectly both the outcome of the various phases of the medicines development projects and the safety of the research subjects involved. The participating medical practitioner retains the overriding responsibility and the final decision to stop a trial if the well-being of the research subjects is seriously endangered. All the team members should follow the main ethical principles governing human research, the respect for autonomy, justice, beneficence and non-maleficence. Nevertheless, the weighing of these principles might be different under various conditions according to the specialty of the members. |